IMC

WSE-listed Ukrainian agricultural producer IMC reported 9M24 sales of $141m (+43% y-o-y), a gain from change in fair value of biological assets (IAS 41) of $62m (+2.6x), EBITDA of $71m (+5.1x; incl. IFRS 16), and net income of $47m (vs. net loss of $2.3m in 9M23). Based on these figures, IMC booked 3Q24 sales of $32m (+21% y-o-y), an IAS 41 gain of $35m (+88x), EBITDA of $33m (vs. -$3.2m in 3Q23), and net income of $26m (vs. $8.5m net loss in 3Q23), for EBITDA and net margins of 49.9% (+61.7pp y-o-y) and 38.3% (+69.7pp).

WSE-listed Ukrainian agricultural producer IMC reported 1H24 sales of $108m (+51% y-o-y), a gain from change in fair value of biological assets (IAS 41) of $28m (+19%), EBITDA of $38m (+121%; incl. IFRS 16), and net income of $22m (+3.4x). Based on these figures, IMC booked 2Q24 sales of $49m (+64% y-o-y), an IAS 41 gain of $27m (+25%), EBITDA of $33m (+112%), and net income of $25m (+144%), for EBITDA and net margins of 67.7% (+15.4pp y-o-y) and 51.6% (+16.9pp).